1 / 22

Appropriate Long Term Prescribing and Polypharmacy

Appropriate Long Term Prescribing and Polypharmacy. Alpana Mair Dr Gregor Smith. Some Background: The ageing population. 62% projected rise in over 65s 2006-31 144% projected rise in over 85s 2006-31 Increased prevalence of LTC, esp COPD and Diabetes

dexter-bennett
Download Presentation

Appropriate Long Term Prescribing and Polypharmacy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Appropriate Long Term Prescribing and Polypharmacy Alpana Mair Dr Gregor Smith

  2. Some Background: The ageing population • 62% projected rise in over 65s 2006-31 • 144% projected rise in over 85s 2006-31 • Increased prevalence of LTC, esp COPD and Diabetes • 24% projected rise in older people admitted as emergencies by 2016 • Would require an extra £3.5 billion 2031 Audit Scotland

  3. Multiple Morbidities • “Multiple conditions”: presence of 2 or more LTC • Largely the norm but associated with poorer outcomes • More people in Scotland with MM below 65 years than above • Develops around 10 years earlier in deprived areas • Associated with more medical errors

  4. Multimorbidity in Scotland Mercer, Guthrie, Wyke: Scottish School of Primary Care

  5. Most people with any long term condition have multiple conditions in Scotland Mercer, Guthrie, Wyke: Scottish School of Primary Care

  6. Mercer, Guthrie, Wyke: Scottish School of Primary Care

  7. Pr. Bruce Guthrie, Dundee

  8. Pr. Bruce Guthrie, Dundee

  9. Contributory Factors • AGE • Non age factors that contribute to developing polypharmacy include: • Multiple morbidities • Residence in long term care home • Hospitalisation, esp repeat episodes of care • Patient expectation • GP attitude • Consultation with several doctors

  10. Polypharmacy: associated dangers • Adverse drug event • Confusion • Falls • Interactions • Drug – drug Interaction • Drug – Disease Interaction • Poor compliance and concordance

  11. Drugs commonly associated with admissions due to ADR • NSAIDs 29.6% • Diuretics 27.3% • Warfarin 10.5% • ACE 7.7% • Antidepressants 7.1% • Beta blockers 6.8% • Opiates 6.0% • Digoxin 2.9% • Prednisolone 2.5% • Clopidogrel 2.4%

  12. High Risk Combinations • NSAID plus any of: • ACE or ARB + diuretic (triple whammy) • eGFR <60 • Diagnosis heart failure • Warfarin • Age >75 without PPI

  13. High Risk Combinations • Warfarin Plus any of: • Another antiplatelet • NSAID • Macrolide • Quinolone • Metronidazole • Azole antifungal

  14. High Risk Combinations • Heart Failure diagnosis plus any of: • Glitazone • NSAID • Tricyclic antidepressant

  15. Drugs Poorly Tolerated in the Elderly • Digoxin (doses higher than 250mcg) • Antipsychotics • Tricyclic antidepressants • Benzodiazepines • Anti cholinergics • Phenothiazines • Combination painkillers

  16. Special considerations • Orthostatic hypotension • Shared side effects eg sedation, bleeding • Diabetic treatment; optimal HbA1c • Antipsychotic medication • Laxatives • Shortened life expectancy

  17. Drugs which can be associated with rapid symptomatic decline if stopped • ACE inhibitors in heart failure / LVSD • Diuretics in heart failure • Steroids • Drugs for heart rate or rhythm control • Anticonvulsants for epilepsy • Antidepressant, antipsychotic, mood stabilisers • amiodarone • Drugs for managing Parkinson’s Dis • Disease modifying anti-rheumatic drugs With caution With specialist advice

  18. CEL 36: November 2012 • Appropriateness of long term prescribing • At medicines review • On starting new medicines • First iteration of National Guidance • Aim – to improve therapeutic care by reducing the risk of adverse drug reactions associated with polypharmacy

  19. GMS Contract 2013 / 14 • Unique negotiated settlement in Scotland • QPQOF – High Risk Patients • Anticipatory Care Plans • Polypharmacy Review • Multi-disciplinary approach • SPARRA risk score 40-60% • 0.75% practice popn 1st yr, rising to 1.5% 2nd yr

  20. Questions? Dr Gregor Smith Alpana Mair

More Related